Neoadjuvant hormonal therapy in radical prostatectomy and radiation-treated patients

Urologia Internationalis

Volumn 65, Issue 2, 2000, Pages 63-67

  Schmid, H P ^a   Semjonow, A ^a   Aus, G ^a   Hertle, L ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; ESTRAMUSTINE PHOSPHATE; LEUPRORELIN;

CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0033755331     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064841     Document Type: Review

References (36)

1. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation
2. Radical perineal prostatectomy subsequent to bilateral orchiectomy
3. Temporary combination therapy with flutamide and tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer
4. Diagnosis and staging of prostatic carcinoma: What is really necessary?
5. Estramustine potentiates the effects of irradiation on the Dunning (R3327) rat prostatic adenocarcinoma
6. 3 prostate cancer: A retrospective study of 22 patients
7. Pathological changes in prostate lesions after androgen manipulation
8. The role of neoadjuvant hormonal manipulation in localized prostatic cancer
9. Preoperative androgen deprivation therapy: Artificial lowering of serum prostate specific antigen without downstaging the tumor
10. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer
11. Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist
12. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial
13. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment
14. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer
15. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer
16. Morphometric and clinical studies on 68 consecutive radical prostatectomies
17. Hormonal treatment before radical prostatectomy: A 3-year follow-up
18. Radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - 24 Months results
19. Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate
20. A randomized trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy: 24 Month post-treatment PSA results
21. Neo-adjuvant hormonotherapy does not facilitate radical prostatectomy
22. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: An in vitro and in vivo study
23. Prognostic factors in carcinoma of the prostate - Analysis of RTOG study 75-06
24. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer
25. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy
26. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the radiation therapy oncology group
27. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate
28. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer
29. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
30. First International Conference on neoadjuvant hormonal therapy of prostate cancer: Overview consensus statement
31. Hormonal therapy of prostate cancer: Are there any news?
32. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: Three versus six months of endocrine therapy
33. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer
34. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure
35. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients
36. Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance